CarThera

<div class="infobox">
<div class="infobox-header">CarThera</div>
<div class="infobox-content">
<table>
<tr><th>Headquarters</th><td>Paris, France</td></tr>
<tr><th>Founded</th><td>2010</td></tr>
<tr><th>Key Product</th><td>SonoCloud</td></tr>
<tr><th>Technology</th><td>Implantable ultrasound for BBB opening</td></tr>
</table>
</div>
</div>

Overview

CarThera is a French medical technology company pioneering implantable focused ultrasound devices for repeated blood-brain barrier (BBB) opening. The company's flagship SonoCloud platform enables clinicians to temporarily disrupt the BBB in a controlled, repeatable manner, enhancing drug delivery to the central nervous system for treatment of brain tumors and neurological disorders including [Alzheimer's disease](/diseases/alzheimers-disease)[@carthera2024].

Unlike external focused ultrasound systems that require precise positioning for each treatment session, SonoCloud is implanted cranium, allowing for multiple treatments without repositioning — a key advantage for chronic conditions like AD that may require ongoing therapeutic delivery.

Company Overview

| Attribute | Details |
|-----------|---------|
| Headquarters | Paris, France |
| Founded | 2010 |
| Founder | Dr. Alexandre Carpentier |
| Key Product | SonoCloud |
| Technology | Implantable focused ultrasound emitter |
| Stage | Phase I/II clinical trials |

Technology Platform

SonoCloud Device

The SonoCloud system consists of:

<div class="infobox">
<div class="infobox-header">CarThera</div>
<div class="infobox-content">
<table>
<tr><th>Headquarters</th><td>Paris, France</td></tr>
<tr><th>Founded</th><td>2010</td></tr>
<tr><th>Key Product</th><td>SonoCloud</td></tr>
<tr><th>Technology</th><td>Implantable ultrasound for BBB opening</td></tr>
</table>
</div>
</div>

Overview

CarThera is a French medical technology company pioneering implantable focused ultrasound devices for repeated blood-brain barrier (BBB) opening. The company's flagship SonoCloud platform enables clinicians to temporarily disrupt the BBB in a controlled, repeatable manner, enhancing drug delivery to the central nervous system for treatment of brain tumors and neurological disorders including [Alzheimer's disease](/diseases/alzheimers-disease)[@carthera2024].

Unlike external focused ultrasound systems that require precise positioning for each treatment session, SonoCloud is implanted cranium, allowing for multiple treatments without repositioning — a key advantage for chronic conditions like AD that may require ongoing therapeutic delivery.

Company Overview

| Attribute | Details |
|-----------|---------|
| Headquarters | Paris, France |
| Founded | 2010 |
| Founder | Dr. Alexandre Carpentier |
| Key Product | SonoCloud |
| Technology | Implantable focused ultrasound emitter |
| Stage | Phase I/II clinical trials |

Technology Platform

SonoCloud Device

The SonoCloud system consists of:

Mechanism of Action

The device operates through the same principle as external FUS[@carpentier2016]:

• Focused Acoustic Energy: Precisely targeted ultrasound waves
• Cavitation Induction: Acoustic pressure causes administered microbubbles to oscillate
• Tight Junction Disruption: Mechanical forces temporarily open endothelial tight junctions
• Barrier Restoration: Tight junctions reform within 6-24 hours

Key Differentiators

| Feature | External FUS (Insightec) | SonoCloud (CarThera) |
|---------|-------------------------|---------------------|
| Invasiveness | Non-invasive | Minimally invasive (implant) |
| Repeat treatments | Requires repositioning | Always in position |
| Treatment frequency | Limited by logistics | Can be frequent |
| Cost per treatment | High | Lower after implantation |
| Target precision | Excellent | Excellent |

Clinical Applications

Brain Tumors (Primary Focus)

The most advanced clinical program is for glioblastoma:

• Enhanced chemotherapy delivery (temozolomide, doxorubicin)
• Trastuzumab for HER2-positive tumors
• Combination with immunotherapy

Alzheimer's Disease

CarThera is expanding into AD applications:

• Enhanced anti-amyloid antibody delivery
• Targeting of hippocampal regions
• Potential for chronic, repeat treatments
• Combination with disease-modifying therapies

Other CNS Disorders

• Parkinson's disease
• Multiple sclerosis
• Lysosomal storage disorders

Clinical Evidence

Key Trials

| Trial | Indication | Phase | Status | Key Findings |
|-------|------------|-------|--------|--------------|
| NCT02557028 | Glioblastoma | Phase I | Completed | Safe BBB opening; enhanced drug delivery |
| NCT0374406 | Glioblastoma | Phase I/II | Active | Evaluating efficacy endpoints |
| - | AD | Planning | Preclinical | - |

Published Data

Competitive Landscape

| Company | Device | Approach | Status |
|---------|--------|----------|--------|
| CarThera | SonoCloud | Implantable | Phase I/II |
| Insightec | ExAblate Neuro | External | Phase I/II for BBB |
| NaviFUS | Research system | External | Preclinical |
| BrainSonix | FUS device | External | Discovery |

Development Pipeline

Current Programs

Future Directions

• Smaller implants: Reducing surgical footprint
• Wireless power: Eliminating transcutaneous connections
• Multi-focus arrays: Treating larger brain volumes
• Closed-loop control: AI-driven treatment optimization

Cross-References

• [AD Focused Ultrasound BBB Opening Companies](/companies/ad-focused-ultrasound-bbb-opening-companies)
• [Focused Ultrasound BBB Opening](/therapeutics/focused-ultrasound-bbb-opening)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Insightec](/companies/insightec)
• [AD Neurovascular Therapy Companies](/companies/ad-neurovascular-cerebral-vasculature-therapy-companies)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CarThera discovered through SciDEX knowledge graph analysis: